Excise Raids Hit Novartis Distribution Chain

Multinational pharma major Novartis India has received a minor setback in its distribution network following raids by excise authorities last month at a warehouse of one of its clearing and forwarding (C&F) agents.

Excise officials conducted a raid on the warehouse of a C&F agent following complaints of raised excise claims on some drugs of Novartis. Excise authorities have subsequently barred the agent from clearing anymore shipments of this drug.

Commenting on the raid, a company spokesperson said, "Due to this raid, drug supply was getting affected and we did not want patients to get deprived. So we decided to make part payments under protest thereby enabling the agent to clear the products. We are in talks with the authorities with respect to the claims raised by them."

The drug in question was a life saving drug, but Novartis executive did not give out the name. The company's net profit had declined last year to Rs 42 crore while its turnover was Rs 438 crore. The turnover, too, declined during the year by 1.8 per cent.

The results declared were the first for the amalgamated entity of Ciba CKD Biochem and Novartis. The profits were affected due to additional costs arising out of the demerger of its agribusiness, high levies, closure of Ciba Vision, amalgamation of CCBl and setting up the consumer health business.

Novartis' pharma sales declined by 3.6 per cent due to an overall slowdown in the market and sluggish offtake of rifampicin. On the other hand, its newly formed consumer healthcare saw a growth of 21 per cent.

The company introduced three new products in this year while it moved five products from the pharma division to the consumer healthcare business in order to promote them as over-the-counter products.

image
Business Standard
177 22
Business Standard

Excise Raids Hit Novartis Distribution Chain

BUSINESS STANDARD 



Multinational pharma major Novartis India has received a minor setback in its distribution network following raids by excise authorities last month at a warehouse of one of its clearing and forwarding (C&F) agents.

Excise officials conducted a raid on the warehouse of a C&F agent following complaints of raised excise claims on some drugs of Novartis. Excise authorities have subsequently barred the agent from clearing anymore shipments of this drug.

Commenting on the raid, a company spokesperson said, "Due to this raid, drug supply was getting affected and we did not want patients to get deprived. So we decided to make part payments under protest thereby enabling the agent to clear the products. We are in talks with the authorities with respect to the claims raised by them."

The drug in question was a life saving drug, but Novartis executive did not give out the name. The company's net profit had declined last year to Rs 42 crore while its turnover was Rs 438 crore. The turnover, too, declined during the year by 1.8 per cent.

The results declared were the first for the amalgamated entity of Ciba CKD Biochem and Novartis. The profits were affected due to additional costs arising out of the demerger of its agribusiness, high levies, closure of Ciba Vision, amalgamation of CCBl and setting up the consumer health business.

Novartis' pharma sales declined by 3.6 per cent due to an overall slowdown in the market and sluggish offtake of rifampicin. On the other hand, its newly formed consumer healthcare saw a growth of 21 per cent.

The company introduced three new products in this year while it moved five products from the pharma division to the consumer healthcare business in order to promote them as over-the-counter products.

RECOMMENDED FOR YOU

Excise Raids Hit Novartis Distribution Chain

Excise Raids Hit Novartis Distribution Chain

Multinational pharma major Novartis India has received a minor setback in its distribution network following raids by excise authorities last month at a warehouse of one of its clearing and forwarding (C&F) agents.

Excise officials conducted a raid on the warehouse of a C&F agent following complaints of raised excise claims on some drugs of Novartis. Excise authorities have subsequently barred the agent from clearing anymore shipments of this drug.

Commenting on the raid, a company spokesperson said, "Due to this raid, drug supply was getting affected and we did not want patients to get deprived. So we decided to make part payments under protest thereby enabling the agent to clear the products. We are in talks with the authorities with respect to the claims raised by them."

The drug in question was a life saving drug, but Novartis executive did not give out the name. The company's net profit had declined last year to Rs 42 crore while its turnover was Rs 438 crore. The turnover, too, declined during the year by 1.8 per cent.

The results declared were the first for the amalgamated entity of Ciba CKD Biochem and Novartis. The profits were affected due to additional costs arising out of the demerger of its agribusiness, high levies, closure of Ciba Vision, amalgamation of CCBl and setting up the consumer health business.

Novartis' pharma sales declined by 3.6 per cent due to an overall slowdown in the market and sluggish offtake of rifampicin. On the other hand, its newly formed consumer healthcare saw a growth of 21 per cent.

The company introduced three new products in this year while it moved five products from the pharma division to the consumer healthcare business in order to promote them as over-the-counter products.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard